The four representative adverse reactions of bevacizumab include hypertension, bleeding, proteinuria, and thromboembolism (5).Bevacizumab is an inhibitor of VEGF, which has the function of maintaining normal vascular endothelial cells, so blocking the VEGF pathway can lead to endothelial dysfunction (6).Vascular endothelial cell apoptosis or inhibition of endothelial cell regeneration can destroy the integrity of endothelial cells. This evidence concerns the gene VEGFA and endothelial dysfunction.